Ratings Omda

Equities

CSAM

NO0010894512

Real-time Oslo Bors Other stock markets 05:13:01 2024-06-13 am EDT			5-day change	1st Jan Change
39.5 ^NOK	+2.60%		+5.33%	+6.76%

Jun. 05	Omda AS (OB:OMDA) commences an Equity Buyback Plan under the authorization approved on April 25, 2024.	CI
May. 28	Software Group Omda Launches NOK30 Million Share Buyback	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
One of the major weak points of the company is its financial situation.
The company appears highly valued given the size of its balance sheet.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Over the past four months, analysts' average price target has been revised downwards significantly.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
OMDA	+6.76%	74.84M		-
VEEVA SYSTEMS INC.	-1.88%	30.54B		C
PRO MEDICUS LIMITED	+39.02%	9.1B		C-
SECTRA AB	+40.13%	4.81B		B-
EVOLENT HEALTH, INC.	-29.79%	2.66B		C-
VERADIGM INC.	-9.44%	1.6B	-	C+
OMNICELL, INC.	-22.85%	1.33B		B
LUNIT INC.	-37.12%	1.09B		-
SIMULATIONS PLUS, INC.	+10.08%	984M		C
B-SOFT CO.,LTD.	-42.90%	798M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes